RecruitingNCT07185919
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
Studying Familial intrahepatic cholestasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ipsen
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Enrollment
- 10 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2032
Study locations (2)
- Seoul National University Hospital, Seoul, South Korea
- Severance Hospital, Yonsei University Health System, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07185919 on ClinicalTrials.govOther trials for Familial intrahepatic cholestasis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07497724Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)Ipsen
- RECRUITINGNCT07191704A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in SpainIpsen
- RECRUITINGNCT06777914Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary CancersIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06778174Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC)University Medical Center Groningen
- ENROLLING BY INVITATIONNCT03930810NAtural Course and Prognosis of PFIC and Effect of Biliary DiversionUniversity Medical Center Groningen